Association Lyonbiopôle of Lyon at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine

Association Lyonbiopôle

321, avenue Jean-Jaurès, 69007 Lyon

This company is co-exhibitor of
Business France SA

Hall map

MEDICA 2018 hall map (Hall 17): stand A24

Fairground map

MEDICA 2018 fairground map: Hall 17

Our range of products

Product categories

  • 01  Electromedical Equipment / Medical Technology
  • 01.11  Other equipment for electromedicine / medical technology

Other equipment for electromedicine / medical technology

Our products

Product category: Other equipment for electromedicine / medical technology

Clinical innovation

One of the cluster's major challenges in the future will be to optimise and accelerate the transition of technological and biomedical innovation into the diagnostic and therapeutic treatment of patients.

Drawing on two programmes, 'Systems biology and personalised medicine' and 'Sepsis', Lyonbiopole is setting up a new development programme with a much larger scope: the Clinical Innovation Programme.

Crucial to achieving this is the industrial world's rapprochement with the hospital and medical world.
This rapprochement, facilitated by the presence of three CHUs (teaching hospitals) in the Rhône-Alpes region, will help:

  • Improve the identification of clinical needs. The consideration of needs and constraints imposed by the hospital sector (hospital practices and medico-economic and regulatory approaches) from the outset of R&D projects is key to minimising the risk of failure as the project progresses.

  • Promote access to patients and clinical trials. Major concerns for the medicine of tomorrow, such as personalised and systems medicine, put the patient at the centre of the underlying challenges. Access to biological samples and data is therefore crucial for these technological, scientific and medical projects. And in order to ensure high quality clinical research, SMEs must work with the competent, multidisciplinary CHU teams to set up and carry out clinical trials in an optimal manner.

  • Help SMEs take on board regulations that demand increasingly more of them over time. In fact, it is vital to anticipate ethical, regulatory and medico-economic questions in order to achieve operational validation and the industrial development of innovations. Coordination with regulatory bodies enables a more effective transition of the innovation to clinical applications.

  • Position clinical innovation players from the Rhône-Alpes region in Europe, in conjunction with the European project CASyM.

In order to ensure the effectiveness of such a rapprochement, Lyonbiopole draws on the solid foundations acquired through its two other programmes and existing structures in the Rhône-Alpes region to support clinical and technological innovation.


In 2013, a first initiative was launched: the implementation of a specific module to raise awareness and provide information to SMEs about the hospital field and its innovation and clinical research tools.


These sessions were held at Louis Pradel Hospital in Bron and were led by Professor Michel Ovize (listen to his interview, in french):


  • Structuring hospital research: partnership opportunities
  • Organising clinical research at the CHU, with a case study of setting up a full-scale trial at the hospital

The first Clinical Innovation Day was held on 20 November 2014.

More Less

About us

Company details

Lyonbiopole missions
As a Cluster, Lyonbiopole is the gateway to healthcare innovation in the Auvergne-Rhône-Alpes region.

It’s supporting ambitious projects and innovative companies in the healthcare & life sciences’ sector. Its aim is to help innovators develop new technologies, products and services in a push toward a more personalized medicine and better treatments for patients.

Its role

Gathering a 200 members community

  • 6 founders : 4 word class industrials (Sanofi Pasteur, bioMérieux, Bohringer Ingelheim Animal Health, BD),  CEA and the Fondation Mérieux,
  • 180 innovative companies
  • 14 research and clinical centers
Its offer support
  • Stimulate innovation
  • Support SMEs development
  • Strengthen the cluster's international position
  • Develop a high-level infrastructure offer

More Less